Suppr超能文献

经动脉化疗栓塞评分评估在肝细胞癌患者经动脉化疗栓塞再治疗决策中的作用

Role of assessment for retreatment with Transarterial chemoembolization score in decision of Retreatment with trans-arterial chemo-embolization Sessions in patients with hepatocellular carcinoma.

作者信息

Abbasi Anwar Hussain, Abid Shahab, Haq Tanveer Ul, Awan Safia

机构信息

Aga khan University Hospital, Karachi, Pakistan.

出版信息

J Ayub Med Coll Abbottabad. 2017 Jul-Sep;29(3):378-383.

Abstract

BACKGROUND

The objective behind this study was to determine that Assessment for Retreatment with Transarterial chemoembolization (ART) score is really applicable in patients with hepatocellular carcinoma.

METHODS

A cross sectional observational study was conducted on all patients with hepatocellular carcinoma of intermediate stage and undergone ≥2 Transarterial chemoembolization. ART score was assessed before and after each session of Transarterial chemoembolization. Multi-logistic regression analysis was performed to compare the final outcome of patients with ART score of ≥2.5 into groups with two and more than two Trans-arterial chemo-embolization sessions.

RESULTS

A total of 100 HCC patients were recruited for final analysis. Our study participants consisted of total 100 HCC patients. Mean Child Pugh score was 6.1±0.95. In our study, most of the study participants (n=63) had ART score of less than 1.5 as compared to ART score >2.5 (n=37). A significant proportion of patients with ART score of <1.5 prior to second Trans-arterial chemo-embolization had better median survival as compared to patients with ART score of >2.5, p-value<0.001. Patients with ART score of more than 2.5 did not show any survival benefit after having 3rd or 4th Trans-arterial chemo-embolization session, p=0.47.

CONCLUSIONS

Our study findings suggest that those HCC patients who receive multiple sessions of TACE with a low ART score have more favourable outcomes with increased survival rate.

摘要

背景

本研究的目的是确定经动脉化疗栓塞(ART)再治疗评估评分在肝细胞癌患者中是否真的适用。

方法

对所有中期肝细胞癌且接受过≥2次经动脉化疗栓塞的患者进行横断面观察研究。在每次经动脉化疗栓塞前后评估ART评分。进行多因素逻辑回归分析,以比较ART评分≥2.5的患者在接受两次及两次以上经动脉化疗栓塞治疗后的最终结局。

结果

共招募了100例肝癌患者进行最终分析。我们的研究参与者共有100例肝癌患者。Child-Pugh平均评分为6.1±0.95。在我们的研究中,与ART评分>2.5(n=37)的患者相比,大多数研究参与者(n=63)的ART评分低于1.5。与ART评分>2.5的患者相比,第二次经动脉化疗栓塞前ART评分<1.5的患者中位生存期显著更长,p值<0.001。ART评分超过2.5的患者在接受第3次或第4次经动脉化疗栓塞后未显示出任何生存获益,p=0.47。

结论

我们的研究结果表明,那些接受多次TACE且ART评分较低的肝癌患者有更有利的结局,生存率更高。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验